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Abstract
Background: Thyrotoxicosis is conceptualized as an ‘‘autoimmune’’ disease with no accepted infectious etiology. There are
increasingly compelling data that another ‘‘autoimmune’’ affliction, Crohn disease, may be caused by Mycobacterium avium
subspecies paratuberculosis (MAP). Like M. tb, MAP is systemic. We hypothesized that some cases of thyrotoxicosis may be
initiated by a MAP infection. Because other thioamides treat tuberculosis, leprosy and M. avium complex, we hypothesized
that a mode of action of some thioamide anti-thyrotoxicosis medications may include MAP growth inhibition.
Methods: The effect of the thioamides, thiourea, methimazole and 6-propo-2-thiouracil (6-PTU) were studied in radiometric
BactecH culture, on ten strains of three mycobacterial species (six of MAP, two of M. avium and two of M. tb. complex). Data
are presented as ‘‘cumulative growth index,’’ (cGI) or ‘‘percent decrease in cumulative GI’’ (%-DcGI).
Principal Findings: Methimazole was the most effective thioamide at inhibiting MAP growth. At 128mg/ml: MAP UCF-4;
65%-DcGI & MAP ATCC 19698; 90%-DcGI. Thiourea inhibited MAP ‘‘Ben’’ maximally; 70%-DcGI. Neither methimazole nor
thiourea inhibited M. avium or M. tb. at the doses tested. 6-PTU has no inhibition on any strain studied, although a
structurally analogous control, 5-PTU, was the most inhibitory thioamide tested.
Significance: We show inhibition of MAP growth by the thioamides, thiourea and methimazole in culture. These data are
compatible with the hypothesis that these thioamides may have anti-prokaryotic in addition to their well-established
eukaryotic actions in thyrotoxic individuals.
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Introduction
Prevailing medical dogma conceptualizes thyrotoxicosis as an
‘‘autoimmune’’ disease, with no universally accepted causative
etiology. The mechanism of the thionamide class of anti-thyroid
medications is accepted to be due to direct action on the
hyperactive eukaryotic thyroid tissue. [1] There are suggestions
that these autoimmune concepts should be readdressed. [2]
There is an intriguing, unexplained, association between thyroid
hyperactivity and other ‘‘autoimmune’’ diseases, notably ‘‘inflam-
matory’’ bowel disease [3] including Crohn disease (CD) [4,5] and
ulcerative colitis (UC.) [6]
As with thyrotoxicosis, the etiology of CD and UC is
(are) not known. Mycobacterium avium subspecies paratuberculosis
(MAP), causes a chronic wasting diarrheal disease in cattle
called Johne disease [7], that is evocative of CD. There are
increasing direct [8] (& see [9] for review) and circumstantial
data [10,11] that MAP is zoonotic.[12] Intriguingly, the
presence of MAP has been documented in a patient with
thyrotoxicosis. [13]
It is of considerable interest that the thioamides ethionamide
and prothionamide are used in the therapy of leprosy,
tuberculosis and M. avium complex infections diseases[14,15],
and thiourea isoxyl is active against M. tb. [16] Additionally
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11099both of the antithyrotoxic medications Methimazole and
Propothiouricil inhibit M. leprae in the mouse footpad
model.[17–19]
Accordingly, we hypothesized that anti-thyrotoxicosis
thioamide medications in addition to their multifold well
documented eukaryotic actions [1], may have prokaryote activity
in thyrotoxic individuals. Specifically, we hypothesized that
these medications may interfere with the growth kinetics
of MAP. The clinical responses to these anti-thyroid medica-
tions are idiosyncratic. Therefore, we further hypothesized
that any MAP culture inhibition would be strain and agent
specific.
We herein report on the effect on the growth kinetics on MAP,
of the thioamide anti-thyroid medications methimazole and 6-
propo-2-thiouricil (6-PTU) as well as thiourea, (an integral
structural component of both methimazole and 6-PTU.) M. leprae
cannot be grown in culture. [20] Therefore, as experimental
control mycobacteria we studied the M. avium and the M.
tuberculosis complexes.
Methods
This study was approved by the Research & Development
Committee at the VAMC Bronx NY (0720-06-038) and was
conducted under the Institutional Radioactive Materials Permit
(#31-00636-07).
Bacterial Culture
Our BactecH 460 (Becton-Dickinson Franklin Lakes NJ)
14C
radiometric culture inhibition methods have previously been
published in detail. [21–26] Because of interference with the assay
[25], we do not use the detergent Tween 80 (recommended to
prevent mycobacterial clumping) in culture. [27] Except for the
amount of test agent, every vial has the identical concentration
of all constituents (including identical 3.2% concentration of
the dissolving agent, DMSO.) Vials are assayed on a daily
basis, quantifying the amount of
14C released as
14CO2,b y
the integral detector in the Bactec 460. The data are obtained
as a manufacturer determined, arbitrary Growth Units (GU) of
0-999.
In this study we evaluated ten strains of mycobacteria, six of
which were MAP. Four MAP strains had been isolated from
humans with Crohn’s disease. ‘‘Dominic’’ (ATCC 43545), ‘‘Ben’’
(ATCC 43544) (both originally isolated by R. Chiodini [28]) and
UCF 4 and ST-5 (both gifts of Saleh Naser, Burnett College of
Biomedical Sciences, University of Central Florida, Orlando
FL.)[8]. The other two MAP strains were from ruminants with
Johne disease, ATCC 19698 and 303 (gift of Michael Collins
Madison WI.) The M. avium subspecies avium strains (hereinafter
called M. avium) were ATCC 25291 (veterinary source) and M.
avium 101 [29]. To study the M. tuberculosis complex, we used two
BioSafety level 2 strains, Bacillus Callmette Guerin (BCG) M. bovis
Figure 1. Shown are the cumulative Growth Indices (cGI) for the four MAP strains isolated from humans with Crohn disease. The
positive control is Monensin, and the negative control is Phthalimide. Note that 5-PTU is consistently the most effective agent, and 6-PTU exhibits no
inhibition. Methimazole is consistently more effective than Thiourea.
doi:10.1371/journal.pone.0011099.g001
Thioamides & MAP
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11099Karlson & Lessel (ATCC 19015) and an avirulent M. tb strain;
ATCC 25177 (all ATCC from ATCC Rockville MD).
The agents used to treat thyrotoxicosis that we studied were: 6-
Propylthiouracil (6-propyl-2-thiouracil; 6-PTU; Sigma Cat #
P3755) and methimazole (1-Methyl-2-imidazolethiol, 2-Mercap-
to-1-methylimidazole; Sigma Cat # M8506).[1,30] We addition-
ally studied Thiourea (Sigma Cat # T8656), an integral structural
component found in both 5-PTU and methimazole (See Fig 1 in
[1]). As an additional control, we studied a structural analog of
PTU, 5-propyl-2-thiouracil (5-PTU; Sigma Cat # P0643.) Our
positive antibiotic controls was monensin [24] and the negative
control was the gluterimide antibiotic phthalimide.[25]
Chemical were dissolved in DMSO, aliquoted, stored at
280uC, thawed, used once and discarded. (All Sigma, St Louis.
MO.) Agents were studied at concentrations ranging from 0.25 to
128 mg/ml (See Figures.)
For clarity and ease of understanding data are presented in two
ways. Graphically (Figures 1–4) we present data for individual
mycobacteria from a single experiment. Data are presented as the
cumulative Growth Index (cGI.) The same data are then
manipulated mathematically (1) and are presented (see Tables 1–6)
as change in growth kinetics as the ‘‘percent change from control
cGI’’ (Increase as ‘‘%+DcGI’’ or Inhibition; ‘‘%2DcGI’’) Each
Table has data from a single chemical agent but every mycobac-
terium studied. This is in contrast to the Figures where each graph is
for an individual mycobacterium.
During the course of these experiments, for technical reasons,
the doses tested were progressively modified. There were four
ranges. In every experiment the doses ranged from ‘‘Minimal’’
(0.25–2 mg/ml), to ‘‘Low’’ (4–8 mg/ml,), to ‘‘Medium’’ 16–32 mg/
ml and ‘‘Maximal’’ doses (64–128 mg/ml.) See individual Figures
for actual dosage tested in each separate experiment. See [22] for
Figure 2. Shown are the cumulative Growth Indices (cGI) for the two MAP strains isolated from ruminants with Johne disease. The
positive control is Monensin, and the negative control is Phthalimide. Note that 5-PTU is consistently the most effective agent, and 6-PTU exhibits no
inhibition. Methimazole inhibits growth. Thiourea does not inhibit MAP 303.
doi:10.1371/journal.pone.0011099.g002
Thioamides & MAP
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‘‘Maximal’’ dose is always the 128mg/ml value.
Results
As previously [24], in this study we show that all MAP strains
are inhibited by Monensin (Table 1 and Figures 1 & 2.) As
previously [24], Monensin does not inhibit one of our two M. avium
control strains (M. avium 101: Table 1 and Figure 3.) In our initial
Monensin manuscript [24], we had only studied BCG from the M.
tb complex. We now additionally study a Biosafety level II non-
virulent strain of M. tb. ATCC 25177. Thus, we find that
Monensin is even more inhibitory against M. tb. ATCC 25177
(298%2DcGI @ 4mg/ml. Table 1 & Figure 4) than it is against
BCG.
The negative control that we use is Phthalimide, a gluterimide
antibiotic that has no mycobacterial inhibition.[25] In this study,
as previously, Phthalimide has no dose dependent inhibition
against any of the mycobacterial strains we study (Table 2 and
Figures 1–4.)
Thiourea, an integral structural component of both 6-PTU and
methimazole, causes dose dependent inhibition of all four MAP
strains isolated from humans (Table 3 and Figure 1). In contrast,
thiourea does not inhibit either the two bovine MAP isolates
(Table 3 and Figure 2) or any of our four mycobacterial controls
species M. avium (Table3 & Figure 3) or M. tb. (Table 3 & Figure 4).
Methimazole, causes dose dependent inhibition of all MAP
strains (Table 4 and Figures 1& 2.) It is most inhibitory on a
bovine MAP isolate ATCC 19698 (90%2DcGI at 128mg/ml.)
Methimazole has no inhibition on our mycobacterial controls,
Figure 3. Shown are the cumulative Growth Indices (cGI) for the two M. avium strains. The positive control is Monensin, and the negative
control is Phthalimide. Note that 5-PTU is consistently the most effective agent. Monensin does not inhibit M. avium 101, replicating previous
findings. [24]
doi:10.1371/journal.pone.0011099.g003
Thioamides & MAP
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Figure 4).
At the doses tested, the anti thyroid medication 6-PTU causes
no inhibition of MAP growth against any strain tested (Table 5 &
Figures 1–4). As a control we compared this to a structural analog,
5-PTU. To our surprise, the control, 5-PTU markedly inhibits
every mycobacterial strain we studied. (Table 6 and Figures 1–4.)
Discussion
Our data show that both thiourea and methimazole cause strain
specific, dose dependent inhibition of MAP in radiometric culture.
Thiourea is more active against the MAP strains isolated from
humans and less active against MAP strains isolated from
ruminants. Methimazole inhibits all MAP strains studied. In
contrast, neither methimazole nor thiourea has any dose
dependent inhibition against our M. avium and M. tb. control
strains. These data could explain the lack of a consistent response
to the medical therapy of clinical thyrotoxicosis.
Other thioamides have antimycobacterial activity in leprosy,
tuberculosis and in M. avium complex infections. [14–16]
Methimazole and 6-PTU inhibit M. leprae.[17–19] In our assay
neither Methimazole nor 6-PTU inhibits M. avium subspecies avium
or the M. tb complex. We conclude that the inhibition of growth
by these antithyroid thioamides is specific to MAP and M. leprae
[17–19], but not to mycobacteria in general.
Our data show no inhibition by 6-PTU on any of the ten
mycobacterial strains we evaluated. These data have multiple
possible explanations. 6-PTU is actively concentrated in vivo by
both lymphocytes (by 666%) [31] and thyroid tissue. [32,33] Thus
the doses achieved in vivo may well exceed the concentrations used
in our culture inhibition study.
Figure 4. Shown are the cumulative Growth Indices (cGI) for the two M. tb complex strains. The positive control is Monensin, and the
negative control is Phthalimide. 5-PTU is consistently the most effective agent. Note that, uniquely in this study, 6-PTU inhibits the BioSafety level 2
avirulent strain of M. tb (ATCC 25177) that we study.
doi:10.1371/journal.pone.0011099.g004
Thioamides & MAP
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these 6-PTU metabolites may have anti-MAP activity. This would
be analogous to 5-ASA inhibiting MAP in culture whereas intact
sulfasalazine, a parent molecule of 5-ASA, has no antiMAP
activity in culture. [22] We have not been able to identify a
commercial source of any 6-PTU metabolites [34,35] to test in our
culture inhibition system.
However, we were able to obtain 5-PTU a structural analog of
6-PTU. 5-PTU markedly inhibits all ten strains of mycobacteria
that we studied. We are unaware of any studies that have
evaluated the safety or efficacy of 5-PTU in the therapy of
thyrotoxicosis. Nor does this study attempt to correlate the clinical
doses given and tissue levels achieved in vivo, with antimycobacter-
ial activity in tissue culture.
The time required to achieve a clinical response in the therapy
of tuberculosis [36], leprosy [37] and IBD [38] is months.
Likewise, a clinical response to thioamide anti-thyrotoxicosis
medication requires months. [1,2] This tardiness is ascribed to
substantial reserves of thyroid hormone, which must be depleted
before a clinical response can be observed. Our data are
Table 1. Positive Control: Monensin.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 227% 292% 295% 276% 256% 230% 212% 7% 276% 229%
Low 248% 292% 298% 295% 278% 272% 221% 13% 298% 266%
Medium 284% 292% 298% 294% 260% 292% 258% 28% 299% 284%
Maximal 291% 294% 299% 295% 290% 293% 243% 22% 298% 295%
Our positive control antibiotic causes dose dependent inhibition in all but M. avium 101.
Shown are the effect of the test agent as either enhancement (%+DcGI) or inhibition of growth (- = %2DcGI) compared to control vials containing the same
concentration of DMSO. See Methods for calculating %2DcGI. The dose ranges are ‘‘Minimal’’ =0.25–2 mg/ml: ‘‘Low’’ =4–8 mg/ml: ‘‘Medium’’ =16–32 mg/ml and
‘‘Maximal’’ =64–128 mg/ml. In these Tables ‘‘Maximal’’ is always the 128mg/ml data. For actual dose tested in individual experiments see the Abscissa on individual
Figures.
doi:10.1371/journal.pone.0011099.t001
Table 2. Negative Control: Phthalimide.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 26% 3% 17% 28% 7% 15% 23% 26% 28% 26%
Low 24% 29% 23% 211% 2% 51% 3% 2% 28% 5%
Medium 9% 24% 24% 7% 22% 61% 9% 24% 24% 15%
Maximal 11% 29% 32% 12% 73% 83% 14% 14% 0% 21%
Our negative control antibiotic has no inhibition in any of the ten mycobacterial strains tested. See Legend to Table 1 for explanation.
doi:10.1371/journal.pone.0011099.t002
Table 3. Thiourea.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 3% 27% 231% 228% 213% 27% 37% 8% 29% 3%
Low 215% 5% 235% 233% 1% 4% 24% 7% 219% 18%
Medium 220% 21% 220% 243% 4% 12% 19% 6% 225% 13%
Maximal 241% 223% 270% 256% 235% 21% 48% 24% 219% 5%
The basic thioamide molecule causes dose dependent inhibition four MAP strains isolated from humans but none of the other six strains. See Legend to Table 1 for
explanation.
doi:10.1371/journal.pone.0011099.t003
Thioamides & MAP
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very slowly. We suggest that successful treatment of a mycobac-
terial trigger for thyrotoxicosis would take months to manifest
clinically.
Other than a single report [13], to our knowledge an association
between MAP and thyrotoxicosis has not been previously
reported. This may be because detecting mycobacteria is not
possible in some forms of mycobacterial diseases such as
tuberculoid leprosy [39] or MAP in humans. [12] We suggest
that to understand human MAP infections, more insights will be
gained from analogies with leprosy [10,11] than with tuberculosis.
The thioamides used to treat thyrotoxicosis have anti M. leprae
effects in an animal model. [17–19] We conclude this prokaryotic
inhibition may have therapeutic implications in thyrotoxicosis.
Our data are compatible with the hypothesis that some cases of
‘‘autoimmune’’ thyroid disease may be instigated by a mycobac-
terial, specifically we posit a MAP, infection.
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Table 4. Methimazole.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 2% 1% 4% 214% 13% 22% 34% 1% 22% 5%
Low 216% 23% 220% 241% 14% 16% 27% 3% 224% 5%
Medium 27% 230% 228% 252% 227% 5% 10% 21% 4% 10%
Maximal 257% 265% 247% 257% 290% 246% 31% 15% 25% 7%
Note dose dependent inhibition in five of six MAP strains, but none of the four Control strains. See Legend to Table 1 for explanation.
doi:10.1371/journal.pone.0011099.t004
Table 5. 5P-2Thiouracil.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 26% 216% 211% 27% 44% 55% 20% 25% 220% 22%
Low 28% 6% 245% 40% 32% 25% 4% 26% 234% 241%
Medium 214% 220% 285% 25% 25% 239% 260% 250% 297% 271%
Maximal 289% 281% 296% 269% 294% 280% 292% 297% 299% 292%
With this structural analog of 6-PTU there is dose dependent inhibition in eight of ten strains and inhibition at 128 mg/ml in the remaining two. Note that M. avium 101
is inhibited. See Legend to Table 1 for explanation.
doi:10.1371/journal.pone.0011099.t005
Table 6. 6P-2Thiouracil.
Dose Range mg/ml MAP M. avium M. tb. complex
Human Bovine M. tb BCG
Dominic UCF4 Ben ST-5 19698 303 25291 101 25177 19015
Minimal 24% 25% 34% 54% 43% 58% 32% 25% 21% 8%
Low 26% 26% 32% 62% 81% 30% 26% 22% 21% 13%
Medium 1% 21% 31% 116% 88% 34% 11% 211% 224% 21%
Maximal 24% 29% 33% 112% 26% 47% 2% 6% 296% 3%
The medication used clinically to treat thyrotoxicosis causes no inhibition in any MAP strain. ‘‘Medium’’ for ATCC 19698 is 64 mg/ml as 32 mg/ml was contaminated. 6-
PTU causes dose dependent inhibition in only M. tb ATCC 25177. See Legend to Table 1 for explanation.
doi:10.1371/journal.pone.0011099.t006
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